+ Watch MDT
on My Watchlist
A medical technology Company alleviating pain, restoring health, and extending life for millions of people around the world.
Medical device makers like MDT have gotten spanked recently by concerns about pricing pressures and an excise tax stemming from the health care reform bill. The CEO preparing to check out didn't exactly help either. That said, I feel that these concerns are overblown. Pricing pressures or no, MDT has the deepest and widest R&D machine in the industry (which should continue to drive growth in the long run) and a crap-ton of pent-up demand for delayable medical procedures that should bolster revenue and eps in the short run. They also enjoy a substantial moat with their existing products, given the reluctance of doctors to switch to new implantations unless they're shown to be clearly superior. Trading at trailing P/E ~13, forward P/E ~10, and a PEG ~1.2 with an S&P-beating, growing dividend, I believe that MDT will prove to be a long-term winner.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions